Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) and Galectin Therapeutics (NASDAQ:GALT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Profitability
This table compares Avenue Therapeutics and Galectin Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
| Galectin Therapeutics | N/A | N/A | -163.15% |
Analyst Recommendations
This is a summary of recent ratings for Avenue Therapeutics and Galectin Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avenue Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Galectin Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Institutional & Insider Ownership
17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by company insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Avenue Therapeutics and Galectin Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | $18.35 | 0.10 |
| Galectin Therapeutics | N/A | N/A | -$41.07 million | ($0.73) | -1.55 |
Galectin Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Avenue Therapeutics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Summary
Galectin Therapeutics beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
About Galectin Therapeutics
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
